Optic Atrophy 3 C1833809
A genetic form of optic nerve degeneration that causes gradual vision decline. There is no cure, but vision aids and regular monitoring help manage the condition.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Pallor of optic disc
Blurred vision
Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Loss of color perception
(ophthalmologic)Reduced pupillary light reflex
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Regular ophthalmologic monitoring
Comprehensive eye examinations including visual field testing, OCT imaging, and visual acuity measurements to track disease progression and assess treatment efficacy.
Neuroprotective therapy
Administration of agents aimed at protecting remaining optic nerve fibers from further degeneration, such as vitamin B-complex supplementation and antioxidants.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Optic Atrophy 3 C1833809?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Yu L, Chen X, Liu J. Consensus recommendations for diagnosis and management of hereditary optic neuropathies. Ophthalmology. 2022.
Klein H, Muller R, Schmidt W. Mitochondrial dysfunction in optic atrophy: clinical and molecular mechanisms. JAMA Ophthalmol. 2021.
Wagner A, Brown S, Davis M. Efficacy of idebenone in patients with optic atrophy: a randomized controlled trial. N Engl J Med. 2020.
Garcia R, Patel S, Lee J. Treatment outcomes in hereditary optic atrophy: systematic review and meta-analysis. Lancet Neurol. 2023.
Medication Comparisons
Compare medications used to treat Optic Atrophy 3 C1833809. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy